A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Latest Information Update: 24 Feb 2025
At a glance
- Drugs MVA CMV (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Feb 2025 Planned End Date changed from 30 Dec 2024 to 1 Jul 2025.
- 13 Mar 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 07 Feb 2023 Planned End Date changed from 14 Dec 2022 to 30 Dec 2023.